Heat-induced gene expression as a novel targeted cancer gene therapy strategy

Cancer Research

Volumn 60, Issue 13, 2000, Pages 3435-3439

  Huang, Qian ^a,c   Hu, Jim K ^a   Lohr, Frank ^a   Zhang, Li ^a   Braun, Rod ^a   Lanzen, Jennifer ^a   Little, John B ^a,b   Dewhirst, Mark W ^a   Li, Chuan Yuan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Shanghai No1 People's Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; HEAT SHOCK PROTEIN 70; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; GENE EXPRESSION; GENE THERAPY; HEAT SHOCK RESPONSE; HYPERTHERMIC THERAPY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE;

ADENOVIRIDAE; ANIMALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEAT; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INTERLEUKIN-12; LUMINESCENT PROTEINS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PROMOTER REGIONS (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034234266     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Spriggs, D., and Yates, S. Cancer chemotherapy: experiences with TNF administration in humans. In: B. Beutler (ed.), Tumor Necrosis Factor: The Molecules and Their Emerging Roles in Medicine, pp. 383-406. New York: Raven Press, 1992.
2. Sigel, J., and Puri, R. Interleukin-2 toxicity. J. Clin. Oncol., 9: 694-704, 1991.
3. Ryffel, B. Interleukin-12: role of interferon-γ in IL-12 adverse effects. Clin. Immunol. Immunopathol., 83: 18-20, 1997.
4. Gossen, M., and Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA, 89: 5547-5551, 1992.
5. Gossen, M., and Bujard, H. Anhydrotetracycline, a novel effector for the tetracycline controlled gene expression systems in eukaryotic cells. Nucleic Acids Res., 21: 4411-4412, 1993.
6. Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W., and Bujard, H. Transcriptional activation by tetracyclines in mammalian cells. Science (Washington DC), 268: 1766-1769, 1995.
7. Hauck, W., and Stanners, C. P. Transcriptional regulation of the carcinoembryonic antigen gene. J. Biol. Chem., 270: 3602-3610, 1995.
8. Richards, C. A., Austin, E. A., and Huber, B. E. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther. 6: 881-893, 1995.
9. Weichselbaum, R. R., Hallahan, D. E., Beckett, M. A., Mauceri, H. J., Lee, H., Sukhatme, V. P., and Kufe, D. W. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res., 54: 4266-4269, 1994.
10. Hallahan, D. E., Mauceri, H. J., Seung, L. P., Dunphy, E. J., Wayne, J. D., Hanna, N. N., Toledno, A., Hellman, S., Kufe, D. W., and Weicheselbaum, R. R. Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med., 1: 786-791, 1995.
11. Joki, T., Nakamura, M., and Ohno, T. Activation of the radiosensitive EGR-1 promoter induces expression of the hepes simplex virus thymidine kinase gene and sensitivity of human glioma cells to gancyclovir. Hum. Gene Ther., 6: 1507-1513, 1995.
12. Dreano, M., Brochot, J., Myers, A., Cheng-Meyer, C., Rungger, D., Voellmy, R., and Bromley, P. High-level, heat-regulated synthesis of proteins in eukaryotic cells. Gene (Amst.), 49: 1-8, 1986.
13. Blackburn, R. V., Galoforo, S. S., Corry, P. M., and Lee, Y. J. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res., 58: 1358-1362, 1998.
14. Aslakson, C., and Miller, F. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res., 52: 1399-1405, 1992.
15. Graham, F. L., and Prevec, L. Methods for construction of adenovirus vectors. Mol. Biotechnol., 3: 207-220, 1995.
16. Voellmy, R., Ahmed, A., Schiller, P., Bromley, P., and Rungger, D. Isolation and functional analysis of a human 70,000-dalton heat shock protein gene segment. Proc. Natl. Acad. Sci. USA, 82: 4949-4953, 1985.
17. Morgan, R., Couture, L., Elroy-Stein, O., Ragheb, J., Moss, B., and Anderson, W. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer transfer system and applications to human gene therapy. Nucleic Acids Res., 20: 1293-1299, 1992.
18. Zhang, W. W., Fang, X., Branch, C. D., Mazur, W., French, B. A., and Roth, J. A. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques, 15: 868-872, 1993.
19. Li, C-Y., Suardet, L., and Little, J. B. Potential role of WAFI/Cipl/p21 as a mediator of TGF-β cytoinhibitory effect. J. Biol. Chem., 270: 4971-4974, 1995.
20. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., and Folkman, J. Inhibition of angiogenesis in vivo by inlerleukin 12. J. Natl. Cancer Inst., 87: 581-586, 1995.
21. Majewski, S., Marczak, M., Szmurlo, A., Jablonska, S., and Bollag, W. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J. Investig. Dermatol., 106: 1114-1118, 1996.
22. Yao, L., Sgadari, C., Furuke, K., Bloom, E. T., Teruya-Feldstein, J., and Tosato, G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood, 93: 1612-1621, 1999.
23. Watanabe, M., McCormick, K. L., Volker, K., Ortaldo, J. R., Wigginton, J. M., Brunda, M. J., Wiltrout, R. H., and Fogler, W. E. Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am. J. Pathol. 150: 1869-1880, 1997.
24. Lasek, W., Feleszko, W., Golab, J., Stoklosa, T., Marczak, M., Dabrowska, A., Malejczyk, M., and Jakobisiak, M. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor a in mice. Cancer Immunol. Immunother., 45: 100-108, 1997.
25. Nasu, Y., Bangma, C. H., Hull, G. W., Lee, H. M., Hu, J., Wang, J., McCurdy, M. A., Shimura, S., Yang, G., Timme, T. L., and Thompson, T. C. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Therapy, 6: 338-349, 1999.
26. Caruso, M., Pham-Nguyen, K., Kwong, Y. L., Xu, B., Kosai, K. I., Finegold, M., Woo, S. L., and Chen, S. H. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. USA, 93: 11302-11306, 1996.
27. Bramson, J. L., Hitt, M., Gauldie, I., and Graham, F. L. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Therapy, 4: 1069-1076, 1997.
28. Zhang, R. Straus, F. H., and DeGroot, L. J. Effective genetic therapy of established medullary thyroid carcinomas with murine interleukin-2: dissemination and cytotoxicity studies in a rat tumor model. Endocrinology, 140: 2152-2158, 1999.
29. Dachs, G., Patterson, A., Firth, J., Ratcliffe, P., Townsend, K., Stratford, I., and Harris, A. Targeting gene expression to hypoxic tumor cells. Nat. Med., 3: 515-520, 1997.
30. Gazit, G., Kane, S., Nichols, P., and Lee, A. Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo. Cancer Res., 55: 1660-1663, 1995.
31. Brizel, D., Scully, S., Harrelson, J., Layfield, L., Bean, J., Prosnitz, L., and Dewhirst, M. Tumor oxygenation predicts the likelihood of distant metastasis in human soft tissue sarcoma. Cancer Res., 56: 941-943, 1996.
32. Vaupel, P. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Klinische Padiatrie, 209: 243-249, 1997.
33. Leopold, K., Oleson, J., Clarke-Pearson, D., Soper, J., Berchuk, A., Samuski, T., Page, R., Blivin, J., Tomberlin, J., and Dewhirst, M. Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 27: 1245-1251, 1993.
34. Sneed, P., Stauffer, P., Gutin, P., Phillips, T., Suen, S., Weaver, K., Lamb, S., Ham, B., Prados, M., Larson, D., and Wara, D. Interstitial irradiation and hyperthermia for the treatment of recurrent malignant brain tumors. Neurosurgery, 28: 206-215, 1991.
35. Vernon, C., Hand, J., Field, S., Machin, D., Whaley, J., van der Zee, J., van Putten, W., van Dijk, J., Gonzalez Gonzalez, D., Liu, F., Goodman, P., and Sherar, M. Radiotherapy with or without hyperthermia in the treatment of superficial breast cancer: results from five randomized controlled trials. Int. J. Radiat. Oncol. Biol. Phys., 35: 731-744, 1996.
36. Anscher, M., Samulski, T., Dodge, R., Prosnitz, L., and Dewhirst, M. Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 37: 1059-1065, 1997.
37. Valdagni, R., and Amicetti, M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int. J. Radiat. Oncol. Biol. Phys., 28: 163-169, 1994.